Table 3 Contraindications, criteria for discontinuation of the infusion and place of administration and monitoring
From: Antenatal magnesium sulphate administration for fetal neuroprotection: a French national survey
Contraindications | n/N (%) |
Renal failure | 33/38 (87) |
Electrolyte disorders | 19/38 (50) |
Cardiovascular disease | 27/38 (71) |
Respiratory distress | 2/38 (5) |
Myasthenia gravis | 23/38 (61) |
Delivery <30 min | 18/38 (47) |
Digitalis interaction | 22/38 (58) |
MgSO4 intolerance | 1/38 (3) |
Stop the infusion if | |
Oliguria <120 mL/4 h | 2/38 (5) |
Oliguria <100 mL/4 h | 29/38 (76) |
Hemodynamic instability | 31/38 (82) |
Respiratory rate < 12/min | 6/38 (16) |
Respiratory rate < 10/min | 28/38 (74) |
Hyporeflexia | 35/38 (92) |
Disorders of consciousness | 33/38 (87) |
Other | 4/38 (1) |
Place of administration | |
Delivery room | 37/38 (97) |
Recovery room | 19/38 (50) |
Intensive care unit | 9/38 (24) |
Obstetrics unit | 8/38 (21) |